STERIS plc (STE) Osake Kurssi
STERIS plc Kurssi
Liikevaihto on kasvanut 8,8 % vuodessa viimeisten 19 vuoden aikana 5,94 Mrd. USD:een. Osakekohtainen tulos on kasvanut 10,1 % vuodessa viimeisten 19 vuoden aikana. STERIS plcn nettomarginaali on nyt 13,2 %, noussut 5,8 %:sta muutama vuosi sitten. STERIS plcn osinkotuotto on tällä hetkellä noin 1,15 %. Jakosuhde on noin 93 % tuloksesta. Osinko on kasvanut 13,5 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 270,00 USD, eli yli nykyhintaa 26,7 %. 16 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
STERIS plc osakekurssi
STERIS plc liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset STERIS plc -osakkeesta
The business model of Steris plc revolves around providing innovative and comprehensive solutions in the healthcare industry. As a global leader, Steris plc focuses on offering products and services that enhance infection prevention, sterilization, and surgical efficiency. With a wide range of offerings including equipment, consumables, and software solutions, Steris plc aims to improve patient outcomes and increase operational productivity for hospitals and healthcare facilities worldwide. Their dedication to advanced technologies and patient safety has earned them a strong reputation in the industry.
Steris plc is primarily active in the healthcare industry. As a global leader, Steris provides innovative solutions and products focused on infection prevention, cleaning, and sterilization for healthcare facilities. With a wide range of offerings, Steris caters to hospitals, ambulatory surgical centers, pharmaceutical companies, and other healthcare institutions. By leveraging its expertise and advanced technologies, Steris aims to enhance patient safety, improve operational efficiency, and support healthcare professionals in delivering high-quality care.
The main competitors of Steris plc in the market include companies such as Johnson & Johnson, 3M Company, and Cantel Medical Corp. These companies operate in the same sector as Steris plc and provide similar products and services. However, Steris plc stands out due to its strong position in the market, diverse product portfolio, and robust customer base. With its innovative solutions and consistent focus on customer satisfaction, Steris plc continues to stay ahead of its competitors in the industry.
Steris plc is a leading global provider of infection prevention and surgical products, services, and technologies. The company was founded in 1985 as Innovative Medical Technologies and later changed its name to Steris Corporation. In 2015, Steris Corporation merged with Synergy Health plc to become Steris plc. With a rich history spanning over three decades, Steris plc has been dedicated to advancing healthcare and related industries. The company offers a wide range of solutions, including sterilization systems, surgical tables, detergents, and disinfectants. Steris plc has established itself as a trusted name in the medical and life sciences sectors, constantly striving to enhance patient safety and improve healthcare outcomes.
Steris plc, a leading company in the medical technology field, has achieved several significant milestones over the years. One noteworthy accomplishment is the acquisition of Synergy Health, which allowed Steris plc to expand its product portfolio and strengthen its global presence. Additionally, the company made strides in research and development, launching innovative solutions such as the Sterrad NX and System 1E, which revolutionized sterilization practices in healthcare settings. Steris plc also gained recognition for its commitment to quality, receiving ISO 9001 certification for its manufacturing facilities. These milestones highlight Steris plc's dedication to delivering advanced and reliable medical technology solutions to its customers worldwide.
Steris plc is primarily present in several countries and regions around the world. As a global company, Steris plc has a significant presence in the United States, where it is headquartered. It also operates in various regions including Europe, Asia, and Latin America. The company's international presence allows it to serve a diverse range of customers and expand its market reach. With a strong focus on providing innovative infection prevention and sterilization solutions, Steris plc continues to establish itself as a leader in the healthcare and life sciences industries worldwide.
Steris plc is a global leader in infection prevention, sterilization, and surgical products and services. The values and corporate philosophy that define Steris plc revolve around their commitment to enhancing healthcare safety and improving the quality of patient care. The company focuses on delivering innovative solutions that enable healthcare professionals to create a safer environment for their patients. Steris plc consistently strives for excellence, constantly innovating and improving to meet the evolving needs of healthcare providers worldwide. With a strong emphasis on integrity, collaboration, and customer-centricity, Steris plc is dedicated to driving positive changes in healthcare practices and improving outcomes for patients.
Analyytikot asettavat tällä hetkellä STERIS plc-osakkeelle keskimääräisen tavoitehinnan 271,33 USD (mediaani: 270,00 USD), mikä merkitsee +27,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.
16 analyytikkoa arvioi tällä hetkellä STERIS plc-osaketta: 11 suosittaa ostoa, 5 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla STERIS plc-osake noteerataan hintaan 190,24 EUR (213,13 USD).
STERIS plc-osake (STE) on listattuna 3 pörssissä, muun muassa: NYSE (STE), London (0XI8.L), Frankfurt (2TG.F).
Steris plc is a globally leading company in the field of sterilization and disinfection of medical instruments and facilities. Its business model is based on three main divisions: Healthcare Products, Healthcare Specialty Services, and Life Sciences. Steris offers a wide range of products and services to ensure effective sterilization and disinfection in the medical field. The company is committed to continuous improvement and innovation to meet customer needs. It also prioritizes sustainability and works closely with customers to develop tailored solutions.
liikevaihto STERIS plc on 5,94 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto STERIS plc on 785,10 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
STERIS plc:n hinta-voitto-suhde (P/E) on tällä hetkellä 26,58. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan STERIS plc-osakkeen arvostusta.
STERIS plc:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,52. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii STERIS plc-osakkeen arvostuskennuslukuna.
STERIS plc:n Eulpool-laatuscore on 8/10.
STERIS plc:n ISIN on IE00BFY8C754. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
STERIS plc:n WKN on A2PGLV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
STERIS plc:n ticker on STE. Tämä pörssinoteeraus käytetään STERIS plc-osakkeiden kauppaan pörssissä.
STERIS plc osake
Kaikki tunnusluvut ja syvällinen analyysi STERIS plc:sta
Meidän osakeanalyysimme STERIS plc-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut STERIS plc:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: